Operating Expense Improvement
Operating expenses were reduced by $9.9 million, marking a 70% improvement over the second quarter of 2024.
Operating and Net Loss Reduction
Operating loss was reduced by $8.7 million, a 71% improvement from the previous year, and net loss improved by $8.7 million or 66% compared to Q2 2024.
MarpaiRx Relaunch
The relaunch of MarpaiRx is proceeding well with nearly 2,000 lives transferred to the program in August, expected to drive future cost savings.
Future Profitability Outlook
The company anticipates reaching profitability by Q1 2026, supported by operating cost reductions and an expected net gain in lives.